In an article published by Scrip Regulatory Affairs, life sciences partner Katherine Wang comments on China FDA’s first time issued guidance that explains how medical device makers should conduct clinical evaluations of the products they seek to register in China and in which cases they may obtain a clinical study waiver. However,
Katherine anticipates that companies might not find it easy to benefit from the clinical trial waiver opportunity straight away.
This article was published in on May 29, 2015 and available here.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.